A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second- or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer

This trial is testing MK-2870 in people with cervical cancer that has returned or spread to other parts of the body during or after receiving prior treatment. This trial is comparing MK-2870 to standard of care treatments in people with cervical cancer. The treatments that will be used in this trial are pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, and irinotecan.
MK-2870 is experimental. It has not been approved to treat any type of cancer.
This trial is being done to: Test the safety of MK-2870. See how well MK-2870 works compared to standard treatment. See if participants who get MK-2870 live longer compared to those who get standard treatment. See if participants who get MK-2870 have a better quality of life compared to those who get standard treatment